XML 109 R77.htm IDEA: XBRL DOCUMENT v3.19.1
Merger with Aravive Biologics, Inc. - Schedule of Estimate Purchase Price Fair Value Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed (Detail) - Aravive Biologics [Member]
$ in Thousands
Oct. 12, 2018
USD ($)
Consideration  
Common stock issued - 5,141,915 shares issued at $7.26 per share $ 37,331
Transaction costs 2,076
Total consideration 39,407
Assets acquired and liabilities assumed  
Cash 5,277
Deferred revenue (1,517)
Contingent payable (264)
Other assets and liabilities (2,768)
Total net assets acquired 39,407
In-process research and development [Member]  
Assets acquired and liabilities assumed  
Acquired identifiable intangible assets at fair value 38,313
Assembled Workforce [Member]  
Assets acquired and liabilities assumed  
Acquired identifiable intangible assets at fair value $ 366